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SUMMARY. Fluconazole is a synthetic triazole antifungal agent used in the treatment of candidiasis and
other fungal infections. A high performance liquid chromatographic method and a microbiological assay
have been developed for the determination of fluconazole in injectable solutions. A Phenomenex Synergi
Fusion RP-80 C18 (150 x 4.60 mm, 4 μm) column was used for fluconazole separation, using isocratic elu-
tion with water: methanol (55:45, v/v) and UV detection at 260 nm. Microbiological assay (bioassay) was
performed using the agar diffusion method, using Saccharomyces cerevisiae ATCC 1600 as the test mi-
croorganism and antibiotic medium 19 for agar layer. The two methods were validated and applied for
quantitative determination of fluconazole and have demonstrated good linearity, precision and accuracy.
The assays were linear in the concentration range of 25-200 μg ml–1, for HPLC, and 25-400 μg ml–1 for mi-
crobiological method. The precision of the methods was determined by repeatability (RSD 0.18%, for
HPLC, and 3.0% for bioassay) and intermediate precision (RSD 0.32%, for HPLC, and 4.73% for bioas-
say). The accuracy was determined and the mean recovery was found to be 99.25%, for HPLC, and
98.89% for bioassay. The two proposed methods have been successfully validated and may be considered
for routine analysis of fluconazole in pharmaceutical injectable preparations.
RESUMEN. “Ensayo Microbiológico y Método por HPLC para la Determinación de Fluconazol en Formulacio-
nes Farmacéuticas Inyectables”. Fluconazol es un agente antifúngico triazólico sintético empleado en el trata-
miento de la candidiasis y de otras infecciones fúngicas. Un método por cromatografía líquida de gran eficacia y
un ensayo microbiológico fueron desarrollados para la determinación de fluconazol en soluciones inyectables.
Una columna Phenomenex Synergi Fusion RP-80 C18 (150 x 4.60 mm, 4 μm) fue usada para la separación, utili-
zando elución isocrática con agua: metanol (55:45, v/v) y detección por ultravioleta a 260 nm. El ensayo micro-
biológico (bioensayo) fue realizado utilizando el método por difusión en agar, empleando Saccharomyces cerevi-
siae ATCC 1600 como microorganismo test y medio antibiótico 19 como medio de cultivo. Los dos métodos re-
sultaron válidos y fueron aplicados para la determinación cuantitativa de fluconazol, demostrando buena lineali-
dad, precisión y exactitud. Los ensayos fueron lineales en la franja de concentración de 25-200 μg ml–1, para el
método por HPLC y 25-400 μg ml–1, para el método microbiológico. La precisión de los métodos fue determina-
da como repetibilidad (DPR 0,18%, por HPLC y 3,0% por el bioensayo) y precisión intermediaria (DPR 0,32%,
por HPLC y 4,73% por el bioensayo). La exactitud fue determinada y la recuperación media encontrada fue
99,25%, por HPLC y 98,89% por el bioensayo. Los dos métodos propuestos resultaron válidos y pueden ser em-
pleados para el análisis de rutina de fluconazol en preparaciones farmacéuticas inyectables.
INTRODUCTION
The increase in the incidence of fungal infec-
tions may be attributed primarily to an increase
in the number of individuals at risk for these in-
fections 1. Fluconazole (Fig. 1) is a triazole anti-
fungal agent widely used in clinical practice,
and has a broad range of applications in the
treatment of both superficial and systemic my-
coses 2. The favorable pharmacokinetics of flu-
conazole (high oral bioavailability, minimal me-
tabolization, low protein binding in plasma, and
predominant renal excretion as unchanged
drug) facilitate the management of its dosing 3.





da infections and the meningitis caused by
Crypctoccus neoformans, typical diseases of im-
munocompromised individuals.
Some analytical methods have been pub-
lished for fluconazole determination in pharma-
ceutical formulations using liquid chromatogra-
phy 4 and spectrophotometry 5-8. Several proce-
dures have been described for the determina-
tion of fluconazole in plasma: chromatographic
9-13 and microbiological 2,14 methods. However,
the microbiological assay for determination of
fluconazole in pharmaceuticals has not yet been
reported.
In this paper, a simple, rapid and economi-
cal HPLC method and a new microbiological as-
say have been developed and validated for
quantitative determination of fluconazole in
pharmaceutical injectable preparations.
MATERIALS AND METHODS
Fluconazole standard substance (assigned
purity 99.28%) was obtained from DEG (São
Paulo, Brazil). Samples of fluconazole injection
200 mg bags containing 2 mg ml–1 in sodium
chloride and water were obtained from com-
mercial sources from the respective manufactur-
ers, and used within their shelf life period. All
solvents were HPLC grade, and all reagents
were of analytical grade. Methanol was obtained
from Tedia (Fairfield, USA). Water was purified
with WaterPro™ PS, Labconco system (MO,
USA). All solvents were filtered through a 0.45
µm nylon membrane filter (Whatman, USA) and
degassed before use. The solutions were filtered
through 0.22 µm Millex-HV filter units (Milli-
pore, USA) before injection.
HPLC method
Chromatography was performed on a Shi-
madzu (Kyoto, Japan) HPLC system, consisting
of two model LC-10ADVP pumps, and a model
SIL-10AF auto-sampler, equipped with UV-vis
detector model SPD-10AVP. Data integration
was performed using Shimadzu Class-VP soft-
ware. Fluconazole was separated on a reversed
phase Phenomenex (CA, USA) Synergi Fusion-
RP 80 C18 (150 x 4.60 mm i.d., 4 µm particle
size) analytical column. All analyses were done
at room temperature (24 ± 2 °C) under isocratic
conditions. The mobile phase consisted of a
mixture of water: methanol (55:45, v/v). The
flow rate was 1.0 ml min–1 and the volume of




The cultures of Saccharomyces cerevisiae
ATCC 1600 (INCQS, Rio de Janeiro, Brazil) were
cultivated on antibiotic medium 19 (Difco, USA),
maintained in the refrigerator and transferred to
another antibiotic medium 19 (24 h before the
assay) which was kept in incubator at 35 ± 1 °C.
The microorganisms were suspended in sterile
NaCl 0.9%. Diluted suspension cultures of 25 ±
2% turbidity were obtained at 580 nm, using a
suitable spectrophotometer (Bausch & Lomb,
USA) and a 13 mm diameter test tube as an ab-
sorption cell against NaCl 0.9% as blank. Por-
tions of 1 ml of the inoculated NaCl 0.9% were
added to 100 ml of antibiotic medium 19 at 45 ±
2 °C and used as inoculated layer.
Assay
The antibiotic medium 19 (15 ml) was
placed into 100 mm x 20 mm Petri dishes for
the agar layer. After solidification of this layer,
six stainless steel cylinders were placed on the
surface of inoculated medium. Three alternated
cylinders were filled with 100 µl of the standard
solutions and the other three with the sample
solutions. After incubation (35 °C for 24 h) the
zone diameters (in mm) of the growth inhibition
were measured using a digital caliper (Starret,
USA). Eight plates were used for each assay.
Preparation of the fluconazole standard
solution
For HPLC method, 25 mg of fluconazole
standard substance was transferred to a 25 ml
volumetric flask and 10 ml of methanol was
added. The flask was sonicated during 5 min,
followed by sufficient quantity of methanol to
obtain 1000 µg ml–1. The resulting solution was
diluted in mobile phase to obtain a final con-
centration of 100 µg ml–1. All solutions were
prepared fresh daily.
For microbiological assay, 10 mg of flucona-
zole standard substance was transferred to a 10
ml volumetric flask and 2 ml of methanol was
added. The flask was sonicated during 5 min,
followed by sufficient quantity of distilled water
to obtain 1000 µg ml–1. The resulting solution
was diluted in distilled water to obtain 100 µg
ml–1.
Preparation of the sample
For HPLC method, a volume of injectable so-
lution equivalent to 20 mg of fluconazole was
transferred to a 20 ml volumetric flask, followed
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by sufficient quantity of mobile phase. The re-
sulting solution was diluted in mobile phase to
obtain 100 µg ml–1.
For microbiological assay, a volume of in-
jectable solution equivalent to 20 mg of flucona-
zole was transferred to a 20 ml volumetric flask,
followed by sufficient quantity of distilled water.
The resulting solution was diluted in distilled
water to achieve final concentrations of 25, 100
and 400 µg ml–1.
Method validation
The methods were validated according to the
International Conference on Harmonisation
guidelines for validation of analytical procedures
15. Analysis of variance (ANOVA) was used to
verify the validity of the methods.
Linearity
For HPLC method, the calibration curve was
obtained with six concentrations of the standard
solution (25-200 µg ml–1). For microbiological
assay, the calibration curve was obtained with
three concentrations of the standard solution
(25-400 µg ml–1). The solutions were prepared
and analyzed in three different days. The lineari-
ty was evaluated by linear regression analysis,
which was calculated by the least square regres-
sion method.
Precision
The precision of the assay was determined
by repeatability (intra-day) and intermediate
precision (inter-day). Intra-day precision was
evaluated by assaying samples at the same con-
centration and on the same day. Six sample so-
lutions (100 µg ml–1) were prepared and as-
sayed. The intermediate precision was studied
by comparing the assays on different days
(three days).
Accuracy
The accuracy was evaluated by the assay of
three concentrations of the sample solution (80,
100 and 120 µg ml–1, for HPLC method; 75, 150,
and 300 µg ml–1, for microbiological assay) in
triplicate. The solutions were prepared and ana-
lyzed in three different days.
Robustness
The robustness of the HPLC method was de-
termined by the analysis of the samples under a
variety of conditions by making small changes
in the percentage of methanol (5%) in the mo-
bile phase, in the flow rate (0.8-1.2 ml min–1)
and by changing the chromatographic column.
RESULTS AND DISCUSSION
HPLC method
A simple and rapid reversed-phase HPLC
method was proposed for the quantitative deter-
mination of fluconazole in pharmaceutical in-
jectable dosage form. Based on physical-chemi-
cal characteristics of fluconazole, the proposed
method employed a C18 chromatographic col-
umn. The retention time observed (4.9 min) al-
lowed a rapid determination of the drug. The
mobile phase is easy to prepare and uses low-
cost solvents, such as water and methanol. Fig.
2 shows a representative chromatogram ob-
tained from the analysis of a standard and a
sample solution of fluconazole using the pro-
posed method. As shown in this figure, flucona-
zole formed a symmetrical peak, well separated
from the solvent front.
The calibration curves for fluconazole were
constructed by plotting concentration versus
peak area and showed good linearity in the 25-
200 µg ml–1 range. The representative linear
equation was y = 2019.5x + 1550, with a highly
significant correlation coefficient (r = 0.9999) for
the method. The inter and intra-day precision
were calculated and showed a RSD of 0.32 and
0.18%, respectively. The accuracy was 99.25%,
and was calculated by the agreement between
the theorical value and the value found. The re-
sults and the mean values demonstrating good
precision and accuracy are shown in Table 1.
The experimental values obtained for the deter-
mination of fluconazole are presented in Table
Figure 2. Chromatograms of fluconazole 100 µg ml–1, (A) standard and (B) sample. Phenomenex™ C18 column
(150 x 4.60 mm i.d., 4 µm). Water: methanol (55:45, v/v) as mobile phase. Flow rate 1.0 ml min–1. 260 nm.
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2. Deliberate variation on the chromatographic
conditions had no significant effect on assay re-
sults or on chromatographic performance, con-
firming the robustness of the method.
The proposed method has an advantage
when compared with the method described by
literature 4, which used trishydroxymethyl
aminomethane in phosphate buffer in the mo-
bile phase. Buffers decrease the shelf life of
chromatographic columns. Besides, the pro-
posed HPLC method was validated and success-
fully applied for the determination of flucona-
zole in injectable preparations.
Microbiological assay
In this work, an experimental 3 x 3 design
agar diffusion bioassay, using three dose levels
for each standard and sample, was used follow-
ing the procedure described in the Brazilian
Pharmacopoeia 6. The calculation procedure
usually assumes a direct relationship between
the observed zone diameter and the logarithm
of the applied dose. The corresponding mean
zone diameters for fluconazole standard solu-
tion were: 12.25 mm (RSD = 8.73%) for low
dose, 16.81 mm (RSD = 6.08%) for medium
dose and 21.91 mm (RSD = 3.30%) for high
dose (Fig. 3). The calibration curves for flucona-




HPLC Accuracy a (%) Precision a (RSD%) Accuracy a (%) Precision a (RSD%)
80 100.12 0.13 100.30 0.38
100 98.45 0.17 98.14 0.29
120 99.20 0.24 98.70 0.29
Bioassay Accuracy b (%) Precision b (RSD%) Accuracy b (%) Precision b (RSD%)
75 98.82 4.31 100.34 6.20
150 99.55 2.81 100.03 5.12
300 98.32 1.89 102.1 2.87
Table 1. Intra-day and inter-day accuracy and precision data of HPLC and microbiological methods for flucona-
zole.  a Mean of three determinations for each concentration. b Mean of eight determinations for each concentra-
tion.
Method Sample (µg) Experimental amount (%) [mg (100 ml)-1] RSD (%)
101.43 a 202.87
HPLC 100 101.61 a 203.23 0.35
100.92 a 201.85
103.75 b 207.50
Bioassay 100 101.86 b 203.72 1.14
101.60 b 203.20
Table 2. Results of the determination of fluconazole in injectable solution by HPLC and microbiological meth-
ods.  a Mean of three determinations. b Mean of eight determinations.
Figure 3. Plate obtained from the microbiological as-
say (agar diffusion method). Fluconazole standard at
concentrations 25 (S1), 100 (S2) and 400 µg ml–1 (S3)
and fluconazole injection at concentrations 25 (T1),
100 (T2) and 400 µg ml–1 (T3), using a strain of Sac-
charomyces cerevisiae ATCC 1600 as the test microor-
ganism.
centration (µg ml–1) versus zone diameter (mm)
and showed good linearity in the 25-400 µg ml–1
range. The representative linear equation was y
= 9.2163x + 0.9241, where x is the log dose and
y the diameter zone. The correlation coefficient
was r = 0.9998.
The experimental values obtained for the de-
termination of fluconazole in injectable dosage
form are presented in Table 2. The precision
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and accuracy of the method were studied. The
inter and intra-day precision obtained by the as-
say showed a RSD of 4.73 and 3.0%, respective-
ly. The accuracy was found to be 98.89%. The
results are expressed in Table 1.
The quantification of antimicrobial drugs by
chemical methods such as HPLC and spec-
trophotometry, although precise, cannot provide
a true indication of biological activity 16. The po-
tency of antibiotics may be demonstrated under
suitable conditions by their inhibitory effect on
microorganisms. A reduction in antimicrobial ac-
tivity may also reveal subtle changes not
demonstrable by chemical methods 17. This as-
say has the advantages of using simple appara-
tus and aqueous solvents, reducing the genera-
tion of chemical residues.
The proposed analytical methods were com-
pared using statistical analysis. ANOVA was ap-
plied and did not reveal a significant difference
between the experimental values obtained by
the two methods. The calculated F-value (Fcalc =
0.00711) was found to be less than the tabled F-
value (Ftab = 5.18) at a 1% significance level
(Table 3).
CONCLUSION
The results indicated that the proposed
methods demonstrated good linearity, precision
and accuracy. Analytical results of the samples
were in accordance with those of the standard
solution at the same concentrations. The meth-
ods use simple reagents, with minimum sample
preparation procedures. Both methods enable a
quantitative determination of fluconazole in
pharmaceutical injectable preparations and can
be used in routine analysis.
Amount labelled HPLC Bioassay
(100%) (%) (%)
Amount found* 100.88 100.81
RSD 0.54 1.94
Table 3. Comparison of the two methods for the de-
termination of fluconazole in injectable formulation,
ANOVA test. * Average of six experiments. ANOVA,
(p<0.01). Fcalc = 0.00711; Ftab = 5.18.
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